Get the Stockscreener App
56.05
2.64%
1.3891
Vaxcyte Inc stock is traded at $56.05, with a volume of 61,666.
It is up +2.64% in the last 24 hours and down -0.74% over the past month.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
See More
Previous Close:
$54.66
Open:
$54.77
24h Volume:
61,666
Relative Volume:
0.04
Market Cap:
$8.09B
Revenue:
-
Net Income/Loss:
$-946.53M
P/E Ratio:
-8.0456
EPS:
-6.9664
Net Cash Flow:
$-814.94M
1W Performance:
+1.09%
1M Performance:
-0.74%
6M Performance:
+3.22%
1Y Performance:
+53.16%
1-Day Range:
$54.12
$56.36
1-Week Range:
$54.12
$58.59
52-Week Range:
$29.08
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
56.03 | 7.89B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
485.40 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
674.35 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
907.15 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.37 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.43 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Reiterated | Needham | Buy |
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Vaxcyte Inc (PCVX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TradingKey - TradingKey
Vaxcyte Inc (PCVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vaxcyte Inc (PCVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vaxcyte Inc (PCVX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vaxcyte Inc (PCVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Vaxcyte's VAX-31 a Game-Changer in the Vaccine Landscape - Kavout | AI
Enterprise value to revenue forward of Vaxcyte, Inc. – BX:PCVX - TradingView
Vaxcyte, Inc. Revenue Breakdown – NASDAQ:PCVX - TradingView
ETFs Investing in Vaxcyte, Inc. Stocks - TradingView
Vaxcyte: Clinical-Stage Vaccine Disrupter With Vast Near-Term Potential - Seeking Alpha
Vaxcyte stock consolidates after raising fresh capital and advancing PCVX vaccine pipeline - Ad-hoc-news.de
MSN Money - MSN
Why (PCVX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Vaxcyte Director John Markels Awarded 23,029 Stock Options in July 2026 Equity Grant - Kalkine Media
Form 4 Vaxcyte Inc For: 16 July By Investing.com - Investing.com Nigeria
Vaxcyte, Inc. (PCVX) awards 23,029 stock options to director John Markels - Stock Titan
Vaxcyte, Inc. (PCVX) director files Form 3 reporting zero holdings - Stock Titan
Vaxcyte (NASDAQ: PCVX) adds independent director John Markels, sets $430,000 equity grant - Stock Titan
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $116 - Moomoo
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring an 87% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Vaxcyte Inc. (PCVX) Slides 2.71%, Approaches Key Support at $55.3IV Spike - dars.gov.et
Vaxcyte Inc. (PCVX) Sees Modest Pullback After Recent Rally – Key Support Levels in FocusMcClellan Oscillator - dars.gov.et
Vaxcyte to Participate in Upcoming Investor Conferences - Investing News Network
Vaxcyte Inc develops next-generation vaccines as interest in pneumococcal prevention grows - ad-hoc-news.de
Should Early VAX-A1 Trial Progress Require Action From Vaxcyte (PCVX) Investors? - simplywall.st
Vaxcyte Inc. (PCVX) Surges 6.5% as Vaccine Developer Attracts Renewed Investor InterestIceberg Order - dars.gov.et
Vaxcyte COO Jim Wassil sells $126,736 in PCVX shares By Investing.com - Investing.com Australia
Vaxcyte president and CFO sells $572k in company stock By Investing.com - Investing.com Australia
Vaxcyte president and CFO sells $572k in company stock - Investing.com
Form 4 Vaxcyte Inc For: 6 July By Investing.com - Investing.com Nigeria
[Form 4] Vaxcyte, Inc. Insider Trading Activity - Stock Titan
Vaxcyte COO Jim Wassil sells $126,736 in PCVX shares - Investing.com
Vaxcyte (PCVX) COO logs 2,250-share sale and option exercise in Form 4 - Stock Titan
Affiliate plans 10,000-share sale by option exercise — PCVX - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Biotechnology Innovator with an 86.68% Potential Upside - DirectorsTalk Interviews
PCVXVaxcyte Inc Volatility & Greeks - Finviz
Vaxcyte stock stays tied to pipeline progress. Nasdaq listing and SEC filings frame the setup. - Ad-hoc-news.de
Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now - Yahoo Finance
Vaxcyte Inc. (PCVX) Surges 4% as Vaccine Developer Gains MomentumGap Down Bounce Plays - dars.gov.et
Have Insiders Sold Vaxcyte Shares Recently? - simplywall.st
Form 144 Vaxcyte For: 1 July By Investing.com - Investing.com Canada
PCVX (NASDAQ) director reported three 2,250-share sales and RSU/option items - Stock Titan
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):